Evolving therapeutic approaches to treating acute ischemic stroke

Journal of the Neurological Sciences

Volumn 249, Issue 2, 2006, Pages 101-109

  Weinberger, Jesse M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

New therapies; Stroke treatment

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ALTEPLASE; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIOXIDANT; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CLOMETHIAZOLE; DESMOTEPLASE; DEXTROMETHORPHAN; DEXTRORPHAN; DISUFENTON SODIUM; DIZOCILPINE; ETOMIDATE; GAVESTINEL; GLUTAMIC ACID; ISOFLURANE; LUBELUZOLE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NIMODIPINE; PENTOBARBITAL; PROPOFOL; REMACEMIDE; SEVOFLURANE; TIRILAZAD; UBIDECARENONE; UNINDEXED DRUG;

APOPTOSIS; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; CELL DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE COURSE; HUMAN; HYPOTHERMIA; MEMBRANE STABILIZATION; MODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANESTHETICS; ANIMALS; ANTICONVULSANTS; ANTIOXIDANTS; BRAIN ISCHEMIA; CALCIUM CHANNEL BLOCKERS; CATECHOLAMINES; CELL DEATH; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; GLUTAMIC ACID; HUMANS; HYPOTHERMIA, INDUCED; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; REPERFUSION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33750515629     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.06.010     Document Type: Review

References (82)

1. Kochanek K.D., and Smith B.L. Deaths: preliminary data for 2002. Nat Vital Statistics Rep 54 (2004) 1-6
2. American Heart Association. Heart disease and stroke statistics (2005). http://www.americanheart.org/downloadable/heart/1105390918119HDSStats2005Update.pdf Update. Available from URL: http://www.americanheart.org/downloadable/heart/1105390918119HDSStats2005Update.pdf
3. Adams H., Adams R., Del Zoppo G., and Goldstein L.B. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update. A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36 (2005) 916-923
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
5. Lees K.R., et al., for the SA-NXY-0004 Investigators. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 34 (2003) 482-487
6. Astrup J., Siesjö B.K., and Symon L. Thresholds in cerebral ischemia-the ischemic penumbra. Stroke 12 (1981) 723-725
7. Sharp F.R., Swanson R.A., Honkaniemi J., Kogure K., and Massa S.M. Neurochemistry and molecular biology. In: Barnett H.J.M., Mohr J.P., Stein B.M., and Yatsu F.M. (Eds). Stroke: pathophysiology, diagnosis, and management. 3rd ed. (1998), Churchill Livingstone, New York 51-83
8. 133xenon inhalation. Stroke 6 (1975) 245-256
9. Strandgaard S., Oleson J., Skinhøj E., and Lassen N.A. Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1 (1973) 507-510
10. Fiehler J., von Bezold M., Kucinski T., Knab R., Eckert B., Wittkugel O., et al. Cerebral blood flow predicts lesion growth in acute stroke patients. Stroke 33 (2002) 2421-2425
11. Marchal G., Beaudouin V., Rioux P., de la Sayette V., Le Doze F., Viader F., et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Stroke 27 (1996) 599-606
12. Hakim A.M., Evans A.C., Berger L., Kuwabara H., Worsley K., Marchal G., et al. The effect of nimodipine on the evaluation of human cerebral infarction studied by PET. J Cereb Blood Flow Metab 9 (1989) 523-534
13. Siesjö B.K., Kristián T., and Katsura K.-I. Overview of bioenergetic failure and metabolic cascades in brain function. In: Ginsberg M.D., and Bogousslavsky J. (Eds). Cerebrovascular disease: pathophysiology, diagnosis, and management vol. 1 (1998), Blackwell Science, Inc., Malden, Mass 3-13
14. Wu A., and Fujikawa DG. Effects of AMPA-receptor and voltage-sensitive sodium channel blockade on high potassium-induced glutamate release and neuronal death in vivo. Brain Res 946 (2002) 119-129
15. Endres M., and Dirnagl U. Ischemia and stroke. In: Alzheimer C. (Ed). Molecular and cellular biology of neuroprotection in the CNS. Advances in experimental medicine and biology vol. 513 (2003), Kluwer Academic/Plenum Publishers, New York 455-473
16. Choi D. Glutamate toxicity and diseases of the nervous system. Neuron 1 (1988) 623-634
17. Sorensen A.G., Copen W.A., Ostergaard L., Buonanno F.S., Gonzalez R.G., Rordorf G., et al. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. Radiology 210 (1999) 519-527
18. Kidwell C.S., Alger J.R., and Saver J.L. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 34 (2003) 2729-2735
19. Warach S. New imaging strategies for patient selection for thrombolytic and neuroprotective therapies. Neurology 57 5 Suppl 2 (2001) S48-S52
20. Baird A.E., Benfield A., Schlaug G., Siewert B., Lövblad K.-.O., Edelman R., et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 41 (1997) 581-589
21. Bhardwaj A., Alkayed N.J., Kirsch J.R., and Hurn P.D. Mechanisms of ischemic brain damage. Curr Cardiol Rep 5 (2003) 160-167
22. Kahn R., Panah M., and Weinberger J. Modulation of ischemic excitatory neurotransmitter and γ-aminobutyric acid release during global temporary cerebral ischemia by selective neuronal nitric oxide synthase inhibition. Anesth Analg 84 (1997) 997-1003
23. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., and McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 24 (1988) 543-551
24. Ientile R., Caccamo D., Macaione V., Torre V., and Macaione S. NMDA-evoked excitotoxicity increases tissue transglutaminase in cerebellar granule cells. Neuroscience 115 (2002) 723-729
25. 2+ channels to extracellular oxidative/nitrosative stress in cerebellar granule cells. J Neurochem 92 (2005) 973-989
26. Gürsoy-Özdemir Y., Can A., and Dalkara T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 35 (2004) 1449-1453
27. Mandir A.S., Poitras M.F., Berliner A.R., Herring W.J., Guastella D.B., Feldman A., et al. NMDA but not non-NMDA excitotoxicity is mediated by poly(ADP-ribose) polymerase. J Neurosci 20 (2000) 8005-8011
28. D'Amours D., Desnoyers S., D'Silva I., and Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342 (1999) 249-268
29. Eliasson M.J.L., Sampei K., Mandir A.S., Hurn P.D., Traystman R.J., Bao J., et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 3 (1997) 1089-1095
30. Weinberger J., and Cohen G. Nerve terminal damage in cerebral ischemia: greater susceptibility of catecholamine nerve terminals relative to serotonin nerve terminals. Stroke 14 (1983) 986-989
31. Weinberger J., and Cohen G. The differential effect of ischemia on the active uptake of dopamine, γ-aminobutyric acid, and glutamate by brain synaptosomes. J Neurochem 38 (1982) 963-968
32. Weinberger J., and Nieves-Rosa J. Monoamine neurotransmitters in the evolution of infarction in ischemic striatum: morphologic correlation. J Neural Transm 71 (1988) 133-142
33. Kahn R.A., Weinberger J., Brannan T., Prikhojan A., and Reich D.L. Nitric oxide modulates dopamine release during global temporary cerebral ischemia. Anesth Analg 80 (1995) 1116-1121
34. Globus M.Y.-T., Ginsberg M.D., Dietrich W.D., Busto R., and Scheinberg P. Substantia nigra lesion protects against ischemic damage in the striatum. Neurosci Lett 80 (1987) 251-256
35. Weinberger J., Nieves-Rosa J., and Cohen G. Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-para-tyrosine. Stroke 16 (1985) 864-870
36. Weinberger J., and Nieves-Rosa J. Metabolism of monoamine neurotransmitters in the evolution of infarction in ischemic striatum. J Neural Transm 69 (1987) 269-275
37. Rabinovic A.D., Lewis D.A., and Hastings T.G. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101 (2000) 67-76
38. Johnson Jr. E.M., Greenlund L.J.S., Akins P.T., and Hsu C.Y. Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. J Neurotrauma 12 (1995) 843-852
39. Kerr J.F.R., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 (1972) 239-257
40. Hallenbeck J.M. The many faces of tumor necrosis factor in stroke. Nat Med 8 (2002) 1363-1368
41. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
42. 10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 278 (2003) 28220-28228
43. Atlante A., Bobba A., Calissano P., Passarella S., and Marra E. The apoptosis/necrosis transition in cerebellar granule cells depends on the mutual relationship of the antioxidant and the proteolytic systems which regulate ROS production and cytochrome c release en route to death. J Neurochem 84 (2003) 960-971
44. Zukin R.S., Jover T., Yokota H., Calderone A., Simionescu M., and Lau C.G. Molecular and cellular mechanisms of ischemia-induced neuronal death. In: Mohr J.P., Choi D.W., Grotta J.C., Weir B., and Wolf P.A. (Eds). Stroke: pathophysiology, diagnosis, and management. 4th ed. (2004), Churchill Livingstone, Philadelphia 829-854
45. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
46. Johnston S.C., Fung L.H., Gillum L.A., Smith W.S., Brass L.M., Lichtman J.H., et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 32 (2001) 1061-1068
47. Furlan A., Higashida R., Wechsler L., Gent M., Rowley H., Kase C., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282 (1999) 2003-2011
48. Mahon B.R., Nesbit G.M., Barnwell S.L., Clark W., Marotta T.R., Weill A., et al. North American clinical experience with the EKOS MicroLysUS infusion catheter for the treatment of embolic stroke. AJNR Am J Neuroradiol 24 (2003) 534-538
49. Röther J., et al., for the Kompetenznetzwerk Schlaganfall Study Group. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke < 6 hours. Stroke 33 (2002) 2438-2445
50. Albers G.W. Expanding the window for thrombolytic therapy in acute stroke: the potential role of acute MRI for patient selection. Stroke 30 (1999) 2230-2237
51. Ribo M., Molina C.A., Rovira A., Quintana M., Delgado P., Montaner J., et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 36 (2005) 602-606
52. Parsons M.W., Barber A., Chalk J., Darby D.G., Rose S., Desmond P.M., et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 51 (2002) 28-37
53. Darby D.G., Barber P.A., Gerraty R.P., Desmond P.M., Yang Q., Parsons M., et al. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 30 (1999) 2043-2052
54. Hacke W., et al., for the DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
55. Kidwell C.S., Liebeskind D.S., Starkman S., and Saver J.L. Trends in acute ischemic stroke trials through the 20th century. Stroke 32 (2001) 1349-1359
56. Ovbiagele B., Kidwell C.S., Starkman S., and Saver J.L. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Cardiovasc Med 5 (2003) 441-449
57. Patel P.M., Goskowicz R.L., Drummond J.C., and Cole DJ. Etomidate reduces ischemia-induced glutamate release in the hippocampus in rats subjected to incomplete forebrain ischemia. Anesth Analg 80 (1995) 933-939
58. Muir K.W., and Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke 26 (1995) 503-513
59. Levy D.E., and Brierly JB. Delayed pentobarbital administration limits ischemic brain damage in gerbils. Ann Neurol 5 (1979) 59-64
60. Bhardwaj A., Brannan T., and Weinberger J. Pentobarbital inhibits extracellular release of dopamine in the ischemic striatum. J Neural Transm [Gen Sect] 82 (1990) 111-117
61. Engelhard K., Werner C., Hoffman W.E., Matthes B., Blobner M., and Kochs E. The effect of sevoflurane and propofol on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesth Analg 97 (2003) 1155-1161
62. Hoffman W.E., Pelligrino D., Werner C., Kochs E., Albrecht R.F., and Schulte am Esch J. Ketamine decreases plasma catecholamines and improves outcome from incomplete cerebral ischemia in rats. Anesthesiology 76 (1992) 755-762
63. Koorn R., Kahn R.A., Brannan T.S., Martinez-Tica J., Weinberger J., and Reich D.L. Effect of isoflurane and halothane on in vivo ischemia-induced dopamine release in the corpus striatum of the rat: a study using cerebral microdialysis. Anesthesiology 79 (1993) 827-835
64. Koorn R., Brannan T.S., Martinez-Tica J., Weinberger J., and Reich D.L. Effect of etomidate on in vivo ischemia-induced dopamine release in the corpus striatum of the rat: a study using cerebral microdialysis. Anesth Analg 78 (1994) 73-79
65. Grotta J., and for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke 28 (1997) 2338-2346
66. Diener H.C., et al., on behalf of the LUB-INT-13 Investigators. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 31 (2000) 2541-2543
67. Wahlgren N.G., et al., for the CLASS Study Group. Clomethiazole Acute Stroke Study (CLASS): results of a randomized, controlled trial of clomethizaole versus placebo in 1360 acute stroke patients. Stroke 30 (1999) 21-28
68. Lyden P., et al., on behalf of the CLASS-I/H/T Investigators. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke 33 (2002) 122-128
69. Sacco R.L., et al., for the GAIN Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke. GAIN Americas: a randomized controlled trial. JAMA 285 (2001) 1719-1728
70. Okada Y., Sakai H., Kohiki E., Suga E., Yanagisawa Y., Tanaka K., et al. A dopamine D4 receptor antagonist attenuates ischemia-induced neuronal cell damage via upregulation of neuronal apoptosis inhibitory protein. J Cereb Blood Flow Metab (2005) 1-13 [electronic publication Feb 23]
71. Mohr J.P., Orgogozo J.M., Harrison M.J., Hennerici M., Wahlgren N.G., Gelmers J.H., et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 4 (1994) 197-203
72. Allen G.S., Ahn H.S., Preziosi T.J., Battye R., Boone S.C., Chou S.N., et al. Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308 (1983) 619-624
73. Siesjö B.K., Agardh C.-.D., and Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1 (1989) 165-211
74. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 27 (1996) 1453-1458
75. Enlimolab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57 (2001) 1428-1434
76. Clark W.M., et al., for the Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke. Neurology 49 (1997) 671-678
77. Clark W.M., et al., for the Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 57 (2001) 1595-1602
78. Green A.R., Ashwood T., Odergren T., and Jackson D.M. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther 100 (2003) 195-214
79. Marshall J.W.B., Duffin K.J., Green A.R., and Ridley R.M. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32 (2001) 190-198
80. Lees K.R., et al., for the SAINT I Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med 354 (2006) 588-600
81. Yanamoto H., Nagata I., Niitsu Y., Zhang Z., Xue J.-.H., Sakai N., et al. Prolonged mild hypothermia therapy protects the brain against permanent focal ischemia. Stroke 32 (2001) 232-239
82. Maier C.M., Sun G.H., Kunis D., Yenari M.A., and Steinberg G.K. Delayed induction and long-term effects of mild hypothermia in a focal model of transient cerebral ischemia: neurological outcome and infarct size. J Neurosurg 94 (2001) 90-96